Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. The company’s immune mapping technologies are designed to provide a personalised immune profile. Its immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies.
In this webinar, Aditxt’s CEO, Amro Albanna, is joined by Jason Kolbert, a research analyst at Dawson James. Jason asks Amro about overall business updates and milestones and the company’s acquisition strategy.